NCT05729386View on ClinicalTrials.gov

A Study to Evaluate the Safety, PK of GC2129A in Healthy Volunteers Under Fed Conditions

PHASE1UnknownINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

February 6, 2023

Primary Completion Date

April 17, 2023

Study Completion Date

April 17, 2023

Conditions
Healthy Volunteers
Interventions
DRUG

GC2129A(Period 1)

Linagliptin and Metformin Hydrochloride Tablet

DRUG

Linaglptin 5mg and Metformin Hydrocholoride 1000mg(Period 1)

Linagliptin 5mg/tab and Metformin Hydrochloride 1000mg/tab (2 tablets)

DRUG

GC2129A(Period 2)

Linagliptin and Metformin Hydrochloride Tablet

DRUG

Linaglptin 5mg and Metformin Hydrochloride 1000mg(Period 2)

Linagliptin 5mg/tab and Metformin Hydrochloride 1000mg/tab (2 tablets)

Trial Locations (1)

Unknown

RECRUITING

H Plus YangJi Hospital, Seoul

Sponsors

Lead Sponsor

GC Biopharma Corp
All Listed Sponsors
lead

GC Biopharma Corp

INDUSTRY

NCT05729386 - A Study to Evaluate the Safety, PK of GC2129A in Healthy Volunteers Under Fed Conditions | Biotech Hunter | Biotech Hunter